Miramar, Florida -- Biopharmaceutical technology company Altor Bioscience has received $20 million in new venture capital investment, according to an SEC regulatory filing.
Altor is developing immunotherapeutic agents for the treatment of cancer, autoimmune diseases and viral infections.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
One investor accounted for the entire amount received.
Altor is still seeking $25 million in additional equity investment, according to the filing.
Minimum investment size per investor was listed as $15,000.